Bristol-Myers Squibb agreed to pay $1 million to settle federal allegations the company made a deal to prevent marketing of a generic version of its top-selling Apotex. The antitrust probe earlier led to the firing of Bristol-Myers CEO Peter Dolan and its top lawyer and to the resignation of a senior vice president.

Related Summaries